Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism

NCT01896232 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01896232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01896232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
August 13, 2013
Completion date
January 8, 2015
Enrollment
683 (actual)
Sites
182

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, secondary hyperparathyroidism